ALX Oncology market cap ALXO
Share price times shares outstanding: what the whole company sells for, since 2020.
- Today, Nov 2, 2026
- $189.4M
- Highest close in our data
- $3.3B
- Dec 2020
ALX Oncology is worth $189.4M at the close on Nov 2, 2026, at $1.37 a share.
That is up 156% over the last year and down 91% over five years.
Its highest close in our data was $3.3B in Dec 2020.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $189.4M | $62.4M | $290.4M | +163% |
| 2025 | $72.1M | $21.7M | $116.7M | −16% |
| 2024 | $85.4M | $68M | $845.6M | −88% |
| 2023 | $741.8M | $173.7M | $766.2M | +62% |
| 2022 | $459.3M | $263.2M | $812.6M | −47% |
| 2021 | $870.3M | $870.3M | $3.2B | −73% |
| 2020 | $3.2B | $1.3B | $3.3B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest ALX Oncology's size, closest first, today.
| Company | Market cap |
|---|---|
| ALXOALX Oncology | $189.4M |
| NATRNatures Sunshine Products | $211.5M |
| CRMDCorMedix | $420.1M |
| LFVNLifevantage | $73.5M |
| ARVNArvinas | $491.7M |
| PBYIPuma Biotechnology | $525.5M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| SPROSpero Therapeutics | $60.6M |
| ZVRAZevra Therapeutics | $599.8M |
| COLLCollegium Pharmaceutical | $770.9M |
| ABUSArbutus Biopharma | $791.4M |
| Peer median | $508.6M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on ALX Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.